Other languages I-Mab

Equities

IMAB

US44975P1030

Real-time Estimate Cboe BZX Other stock markets 09:45:33 29/04/2024 pm IST			5-day change	1st Jan Change
1.805 ^USD	+0.28%		+0.08%	-5.19%

18/04	Verastem Names John Hayslip as Chief Medical Officer	MT
15/04	I-Mab Announces Chief Medical Officer Changes	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

I-Mab Announces Chief Medical Officer Changes	16/04
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	02/04
I-Mab Announces Executive Resignation	01/04
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02
Biotech firm I-Mab to divest China operations, shift focus to US	07/02
Biotech firm I-Mab to divest China operations	07/02
I-Mab Announces Board Changes , Effective February 10, 2024	07/02
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading	11/01
I-Mab Says FDA Grants Breakthrough Therapy Designation for Felzartamab to Treat Kidney Disease	02/11
I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy	02/11
I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023	16/23/16
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503	10/23/10
I-Mab Regains Global Rights to Lemzoparlimab	23/23/23
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	31/23/31
Sector Update: Health Care	31/23/31
Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday	31/23/31
I-Mab's Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says	31/23/31
I-Mab announces an Equity Buyback for $40 million worth of its shares.	17/23/17
I-Mab Reports Earnings Results for the Half Year Ended June 30, 2023	17/23/17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages I-Mab

Equities

IMAB

US44975P1030

Other languages

Filters